CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Widespread alterations in microRNA biogenesis in human Huntington’s disease putamen

Petry, Serena, Keraudren, Rémi, Nateghi, Behnaz, Loiselle, Andréanne, Pircs, Karolina, Jakobsson, Johan, Sephton, Chantelle, Langlois, Mélanie, St-Amour, Isabelle, Hébert, Sébastien S.·2022·Acta Neuropathologica Communications
DOI 10.1186/s40478-022-01407-7PMC PMC9308264

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Altered microRNA (miRNA) expression is a common feature of Huntington’s disease (HD) and could participate in disease onset and progression. However, little is known about the underlying causes of miRNA disruption in HD. We and others have previously shown that mutant Huntingtin binds to Ago2, a central component of miRNA biogenesis, and disrupts mature miRNA levels. In this study, we sought to determine if miRNA maturation per se was compromised in HD. Towards this end, we characterized major miRNA biogenesis pathway components and miRNA maturation products (pri-miRNA, pre-miRNA, and mature) in human HD (N = 41, Vonsattel grades HD2-4) and healthy control (N = 25) subjects. Notably, the striatum (putamen) and cortex (BA39) from the same individuals were analyzed in parallel. We show that Ago2, Drosha, and Dicer were strongly downregulated in human HD at the early stages of the disease. Using a panel of HD-related miRNAs (miR-10b, miR-196b, miR-132, miR-212, miR-127, miR-128), we uncovered various types of maturation defects in the HD brain, the most prominent occurring at the pre-miRNA to mature miRNA maturation step. Consistent with earlier findings, we provide evidence that alterations in autophagy could participate in miRNA maturation defects. Notably, most changes occurred in the striatum, which is more prone to HTT aggregation and neurodegeneration. Likewise, we observed no significant alterations in miRNA biogenesis in human HD cortex and blood, strengthening tissue-specific effects. Overall, these data provide important clues into the underlying mechanisms behind miRNA alterations in HD-susceptible tissues. Further investigations are now required to understand the biological, diagnostic, and therapeutic implications of miRNA/RNAi biogenesis defects in HD and related neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-022-01407-7

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 51

  1. Aguiar S, van der Gaag B, Cortese FAB (2017) RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA. Transl Neurodegener 6:30. https://doi.org/10.1186/s40035-017-0101-9 · DOI
  2. Akkoc Y, Gozuacik D (2020) MicroRNAs as major regulators of the autophagy pathway. Biochim Biophys Acta Mol Cell Res 1867:118662. https://doi.org/10.1016/j.bbamcr.2020.118662 · DOI
  3. Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F (2010) Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 277:2268–2281. https://doi.org/10.1111/j.1742-4658.2010.07643.x · DOI
  4. Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AW, Chen CM, Yang SH (2013) miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 93:306–312. https://doi.org/10.1016/j.ajhg.2013.05.025 · DOI · Paper page
  5. Chmielarz P, Konovalova J, Najam SS, Alter H, Piepponen TP, Erfle H, Sonntag KC, Schutz G, Vinnikov IA, Domanskyi A (2017) Dicer and microRNAs protect adult dopamine neurons. Cell Death Dis 8:e2813. https://doi.org/10.1038/cddis.2017.214 · DOI
  6. Cuellar TL, Davis TH, Nelson PT, Loeb GB, Harfe BD, Ullian E, McManus MT (2008) Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci USA 105:5614–5619. https://doi.org/10.1073/pnas.0801689105 · DOI
  7. Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Rowley JW, Cloutier N, Tremblay ME, Vincent AT, Gould PV, Chouinard S et al (2019) Platelet abnormalities in Huntington’s disease. J Neurol Neurosurg Psychiatry 90:272–283. https://doi.org/10.1136/jnnp-2018-318854 · DOI
  8. Dong X, Cong S (2021) MicroRNAs in Huntington’s Disease: Diagnostic Biomarkers or Therapeutic Agents? Front Cell Neurosci 15:705348. https://doi.org/10.3389/fncel.2021.705348 · DOI
  9. Dorval V, Smith PY, Delay C, Calvo E, Planel E, Zommer N, Buee L, Hebert SS (2012) Gene network and pathway analysis of mice with conditional ablation of Dicer in post-mitotic neurons. PLoS ONE 7:e44060. https://doi.org/10.1371/journal.pone.0044060 · DOI
  10. Emde A, Eitan C, Liou LL, Libby RT, Rivkin N, Magen I, Reichenstein I, Oppenheim H, Eilam R, Silvestroni A et al (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J 34:2633–2651. https://doi.org/10.15252/embj.201490493 · DOI · Paper page
  11. Fukuoka M, Takahashi M, Fujita H, Chiyo T, Popiel HA, Watanabe S, Furuya H, Murata M, Wada K, Okada T et al (2018) Supplemental Treatment for Huntington’s Disease with miR-132 that Is Deficient in Huntington’s Disease Brain. Molecular therapy Nucleic Acids 11:79–90. https://doi.org/10.1016/j.omtn.2018.01.007 · DOI
  12. Gan L, Cookson MR, Petrucelli L, La Spada AR (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21:1300–1309. https://doi.org/10.1038/s41593-018-0237-7 · DOI
  13. Guo S, Yang J, Jiang B, Zhou N, Ding H, Zhou G, Wu S, Suo A, Wu X, Xie W et al (2022) MicroRNA editing patterns in Huntington’s disease. Sci Rep 12:3173. https://doi.org/10.1038/s41598-022-06970-6 · DOI
  14. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. The Journal of neuroscience : the official journal of the Society for Neuroscience 19:2522–2534 · DOI · Paper page
  15. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15:509–524. https://doi.org/10.1038/nrm3838 · DOI · Paper page
  16. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buee L, De Strooper B (2010) Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet 19:3959–3969. https://doi.org/10.1093/hmg/ddq311 · DOI
  17. Hernandez-Rapp J, Rainone S, Goupil C, Dorval V, Smith PY, Saint-Pierre M, Vallee M, Planel E, Droit A, Calon F et al (2016) microRNA-132/212 deficiency enhances Abeta production and senile plaque deposition in Alzheimer’s disease triple transgenic mice. Sci Rep 6:30953. https://doi.org/10.1038/srep30953 · DOI
  18. Hernandez-Rapp J, Smith PY, Filali M, Goupil C, Planel E, Magill ST, Goodman RH, Hebert SS (2015) Memory formation and retention are affected in adult miR-132/212 knockout mice. Behav Brain Res 287:15–26. https://doi.org/10.1016/j.bbr.2015.03.032 · DOI · Paper page
  19. Hickman RA, Faust PL, Marder K, Yamamoto A, Vonsattel JP (2022) The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade. Acta Neuropathol Commun 10:55. https://doi.org/10.1186/s40478-022-01364-1 · DOI
  20. Hoss AG, Kartha VK, Dong X, Latourelle JC, Dumitriu A, Hadzi TC, Macdonald ME, Gusella JF, Akbarian S, Chen JF et al (2014) MicroRNAs located in the Hox gene clusters are implicated in huntington’s disease pathogenesis. PLoS Genet 10:e1004188. https://doi.org/10.1371/journal.pgen.1004188 · DOI · Paper page
  21. Jin J, Cheng Y, Zhang Y, Wood W, Peng Q, Hutchison E, Mattson MP, Becker KG, Duan W (2012) Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. J Neurochem 123:477–490. https://doi.org/10.1111/j.1471-4159.2012.07925.x · DOI · Paper page
  22. Kawahara Y, Mieda-Sato A (2012) TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci USA 109:3347–3352. https://doi.org/10.1073/pnas.1112427109 · DOI
  23. Krauss S, Evert BO (2019) The Role of MicroRNAs in Spinocerebellar Ataxia Type 3. J Mol Biol 431:1729–1742. https://doi.org/10.1016/j.jmb.2019.01.019 · DOI
  24. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46:842–849 · DOI
  25. Kumar A, Vaish M, Ratan RR (2014) Transcriptional dysregulation in Huntington’s disease: a failure of adaptive transcriptional homeostasis. Drug Discov Today 19:956–962. https://doi.org/10.1016/j.drudis.2014.03.016 · DOI
  26. Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S et al (2018) MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice. PLoS ONE 13:e0190550. https://doi.org/10.1371/journal.pone.0190550 · DOI
  27. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M et al (2011) Altered microRNA regulation in Huntington’s disease models. Exp Neurol 227:172–179. https://doi.org/10.1016/j.expneurol.2010.10.012 · DOI · Paper page
  28. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X (2010) A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 38:7219–7235. https://doi.org/10.1093/nar/gkq575 · DOI · Paper page
  29. Martinez B, Peplow PV (2021) Altered microRNA expression in animal models of Huntington’s disease and potential therapeutic strategies. Neural Regen Res 16:2159–2169. https://doi.org/10.4103/1673-5374.310673 · DOI
  30. McCann C, Holohan EE, Das S, Dervan A, Larkin A, Lee JA, Rodrigues V, Parker R, Ramaswami M (2011) The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc Natl Acad Sci USA 108:E655-662. https://doi.org/10.1073/pnas.1107198108 · DOI
  31. O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) 9:402. https://doi.org/10.3389/fendo.2018.00402 · DOI · Paper page
  32. Olmo IG, Olmo RP, Goncalves ANA, Pires RGW, Marques JT, Ribeiro FM (2021) High-Throughput Sequencing of BACHD Mice Reveals Upregulation of Neuroprotective miRNAs at the Pre-Symptomatic Stage of Huntington’s Disease. ASN Neuro 13:17590914211009856. https://doi.org/10.1177/17590914211009857 · DOI
  33. Pircs K, Petri R, Madsen S, Brattas PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Bruckner M, Lundh SH et al (2018) Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. Cell Rep 24:1397–1406. https://doi.org/10.1016/j.celrep.2018.07.017 · DOI
  34. Pogoda A, Chmielewska N, Maciejak P, Szyndler J (2021) Transcriptional Dysregulation in Huntington’s Disease: The Role in Pathogenesis and Potency for Pharmacological Targeting. Curr Med Chem 28:2783–2806. https://doi.org/10.2174/0929867327666200705225821 · DOI
  35. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D’Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR et al (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284:10855–10867. https://doi.org/10.1074/jbc.M804813200 · DOI
  36. Rieux M, Alpaugh M, Sciacca G, Saint-Pierre M, Masnata M, Denis HL, Levesque SA, Herrmann F, Bazenet C, Garneau APet al (2020) Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology. Molecular psychiatry: Doi https://doi.org/10.1038/s41380-020-0787-4 · DOI
  37. Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. The Lancet Neurology 10:83–98. https://doi.org/10.1016/S1474-4422(10)70245-3 · DOI
  38. Rub U, Vonsattel JP, Heinsen H, Korf HW (2015) The Neuropathology of Huntington s disease: classical findings, recent developments and correlation to functional neuroanatomy. Adv Anat Embryol Cell Biol 217:1–146 · DOI
  39. Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, Kvann JC, Tomaszewski M, Beaubien F, Cloutier JF, Levesque D et al (2013) Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington’s disease. Genes Brain Behav 12:108–124. https://doi.org/10.1111/j.1601-183X.2012.00858.x · DOI
  40. Savas JN, Ma B, Deinhardt K, Culver BP, Restituito S, Wu L, Belasco JG, Chao MV, Tanese N (2010) A role for huntington disease protein in dendritic RNA granules. J Biol Chem 285:13142–13153. https://doi.org/10.1074/jbc.M110.114561 · DOI
  41. Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhattar R, Markey SP, Tanese N (2008) Huntington’s disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci USA 105:10820–10825. https://doi.org/10.1073/pnas.0800658105 · DOI
  42. Seitz H (2019) On the Number of Functional microRNA Targets. Mol Biol Evol 36:1596–1597. https://doi.org/10.1093/molbev/msz054 · DOI
  43. Sellier C, Freyermuth F, Tabet R, Tran T, He F, Ruffenach F, Alunni V, Moine H, Thibault C, Page A et al (2013) Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep 3:869–880. https://doi.org/10.1016/j.celrep.2013.02.004 · DOI
  44. Sieradzan KA, Mann DM (2001) The selective vulnerability of nerve cells in Huntington’s disease. Neuropathol Appl Neurobiol 27:1–21. https://doi.org/10.1046/j.0305-1846.2001.00299.x · DOI
  45. Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, Buee L, Hebert SS (2011) MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 20:4016–4024. https://doi.org/10.1093/hmg/ddr330 · DOI · Paper page
  46. St-Amour I, Turgeon A, Goupil C, Planel E, Hebert SS (2018) Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease. Acta Neuropathol 135:249–265. https://doi.org/10.1007/s00401-017-1786-7 · DOI
  47. Vidigal JA, Ventura A (2015) The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 25:137–147. https://doi.org/10.1016/j.tcb.2014.11.004 · DOI
  48. Wilczynska A, Bushell M (2015) The complexity of miRNA-mediated repression. Cell Death Differ 22:22–33. https://doi.org/10.1038/cdd.2014.112 · DOI
  49. Wu Y, Dai X, Ni Z, Yan X, He F, Lian J (2017) The downregulation of ATG4B mediated by microRNA-34a/34c-5p suppresses rapamycin-induced autophagy. Iran J Basic Med Sci 20:1125–1130. https://doi.org/10.22038/IJBMS.2017.9446 · DOI
  50. Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J, Li SH, Li XJ (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 163:109–118. https://doi.org/10.1083/jcb.200306038 · DOI
  51. Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 81:294–330. https://doi.org/10.1016/j.pneurobio.2007.01.003 · DOI

Cited by

Sorted by citations

See all 24

Metadata

Authors
Petry, S., Keraudren, R., Nateghi, B., Loiselle, A., Pircs, K., Jakobsson, J., Sephton, C., Langlois, M., St-Amour, I., & Hébert, S. S.
Venue
Acta Neuropathologica Communications
Publisher
Springer Science and Business Media LLC
Published
2022-07-22
Volume
10
Issue
1
ISSN
2051-5960
DOI
10.1186/s40478-022-01407-7
PMC
PMC9308264
Cited by
24
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review